Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Capecitabine | |
| Synonyms |
|
|
| Definitions |
A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1794 |
|
| Accepted_Therapeutic_Use_For |
Breast cancer; Colorectal cancer, Stage III colon cancer
|
|
| ALT_DEFINITION |
A drug used to treat stage III colon cancer in patients who had surgery to remove the cancer. It is also used to treat metastatic breast cancer that has not improved after treatment with certain other anticancer drugs. Xeloda is being studied in the treatment of other types of cancer. It is taken up by cancer cells and breaks down into 5-fluorouracil, a substance that kills tumor cells. Xeloda is a type of antimetabolite.
|
|
| CAS_Registry |
154361-50-9
|
|
| CHEBI_ID |
CHEBI:31348
|
|
| Chemical_Formula |
C15H22FN3O6
|
|
| code |
C1794
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)
|
|
| Display_Name |
Capecitabine
|
|
| FDA_UNII_Code |
6804DJ8Z9U
|
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Capecitabine
|
|
| Legacy Concept Name |
Capecitabine
|
|
| Maps_To |
Capecitabine Xeloda
|
|
| NCI_Drug_Dictionary_ID |
42852
|
|
| NSC Number |
712807
|
|
| PDQ_Closed_Trial_Search_ID |
42852
|
|
| PDQ_Open_Trial_Search_ID |
42852
|
|
| Preferred_Name |
Capecitabine
|
|
| prefixIRI |
NCIT:C1794
|
|
| prefLabel |
Capecitabine
|
|
| Semantic_Type |
Pharmacologic Substance Nucleic Acid, Nucleoside, or Nucleotide
|
|
| UMLS_CUI |
C0671970
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |